$ACT Headlines
UK drug rejection, patent concerns take a bite out of Celgene shares 1:33 p.m. March 14, 2014 - blogs.marketwatch.com
Mylan to start selling generic Celebrex in May 7:22 a.m. March 13, 2014 - MarketWatch.com
Pfizer loses Celebrex patent ruling; shares halted but effect muted 3:21 p.m. March 12, 2014 - blogs.marketwatch.com
Staples awash in red; eBay up as Icahn posts new letter 4:09 p.m. March 6, 2014 - Victor Reklaitis
Icahn Enterprises reports profit up 144% in 2013 10:22 a.m. March 3, 2014 - MarketWatch
Citadel hedge fund’s recent moves 11:12 a.m. Feb. 25, 2014 - Insider Monkey
Stocks rally; S&P 500 ends right below record 4:45 p.m. Feb. 24, 2014 - Victor Reklaitis
U.S. stock market is starting to ride a tech M&A wave 5:31 a.m. Feb. 24, 2014 - Wallace Witkowski
Actavis continues hot streak with better-than-expected earnings 11:21 a.m. Feb. 20, 2014 - blogs.marketwatch.com
Actavis swings to loss on charges, write-downs 8:03 a.m. Feb. 20, 2014 - MarketWatch.com
Pharma megamergers bring higher profits, better returns, study says 1:59 p.m. Feb. 19, 2014 - blogs.marketwatch.com
Actavis, Forest shares continue their climb in aftermath of $25 billion deal 11:03 a.m. Feb. 19, 2014 - blogs.marketwatch.com
U.S. stocks edge up; Nasdaq gains for 8th day in a row 4:38 p.m. Feb. 18, 2014 - Anora Mahmudova
Forest Laboratories, Actavis surge on buyout deal 4:10 p.m. Feb. 18, 2014 - Ben Eisen
S&P 500, Nasdaq extend win streaks but Dow dips: stock market live blog recap 4:06 p.m. Feb. 18, 2014 - blogs.marketwatch.com
Forest buyout may not spell the end of dealmaking for Actavis 3:00 p.m. Feb. 18, 2014 - blogs.marketwatch.com
Pharma ETFs pop on the Actavis-Forest deal 2:07 p.m. Feb. 18, 2014 - blogs.marketwatch.com
Investors drive up price of Actavis-Forest deal 11:14 a.m. Feb. 18, 2014 - blogs.marketwatch.com
Actavis shares jump 7.8% on Forest Lab deal 9:35 a.m. Feb. 18, 2014 - Sue Chang
U.S. stock futures trim rise; Forest Labs soars 9:14 a.m. Feb. 18, 2014 - Sara Sjolin
Veteran Investor's Top Biotech and Drug Stocks 7:07 a.m. Today - Barrons.com
Actavis Prescribes Profits via M&A and Generic Drugs 8:27 p.m. March 16, 2014 - InvestorPlace.com
Actavis, Mylan to Benefit from Celebrex Ruling - Analyst Blog 5:20 p.m. March 14, 2014 - Zacks.com
Horizon Pharma Banks On Two-For-One Arthritis Drugs 1:05 p.m. March 14, 2014 - Investors Business Daily
Why Teva May Be Back From the Dead 10:07 a.m. March 14, 2014 - 247WallSt.com
Teva Pharmaceuticals Stock Could Rise 30% 12:54 a.m. March 14, 2014 - Barrons.com
FDA Approves Mallinckrodt's Xartemis XR - Analyst Blog 6:00 p.m. March 13, 2014 - Zacks.com
Narrower-than-Expected Loss at Supernus - Analyst Blog 9:40 a.m. March 13, 2014 - Zacks.com
Pfizer Says Court Invalidates Celebrex Patent 7:51 a.m. March 13, 2014 - The Wall Street Journal Interactive Edition
Pfizer Loses Patent On Celebrex, Plans To Appeal 2:59 p.m. March 12, 2014 - Investors Business Daily
Icahn Makes Case to eBay Investors 2:32 p.m. March 12, 2014 - The Wall Street Journal Interactive Edition
Greenberg: What You May Have Missed 9:33 a.m. March 12, 2014 - TheStreet.com
Will Horizon Pharma Spike Again On Quarterly Report? 7:02 a.m. March 12, 2014 - Investors Business Daily
How To Invest: Seek Stock Ideas In Sector Leaders 4:23 p.m. March 11, 2014 - Investors Business Daily
Actavis PLC (ACT): Today's Featured Drugs Laggard 5:01 p.m. March 10, 2014 - TheStreet.com
3 Stocks Underperforming Today In The Drugs Industry 1:04 p.m. March 10, 2014 - TheStreet.com
Forest Labs/Adamas Seek FDA Approval - Analyst Blog 5:00 p.m. March 7, 2014 - Zacks.com
Highflying Drug, Biotech Stocks Take Rare Drubbing 4:49 p.m. March 7, 2014 - Investors Business Daily
Merck KGaA Misses 2013 Earnings & Rev Ests - Analyst Blog 10:30 a.m. March 7, 2014 - Zacks.com
Columbia Labs buys back shares 9:30 a.m. March 7, 2014 - Seeking Alpha
New Drug Applications, Earnings Release Schedules, Drug Designations, New Services, and Clinical Trials - Analyst Notes on Actavis, Intercept, GW Pharmaceuticals, Galena, and Conatus 8:00 a.m. March 13, 2014 - PR Newswire - PRF
Actavis Confirms Favorable Ruling in Generic Celebrex® Patent Suit 5:35 p.m. March 12, 2014 - PR Newswire - PRF
Columbia Laboratories Repurchases 1.4 Million Shares of Common Stock from Actavis 6:50 a.m. March 7, 2014 - PR Newswire - PRF
Actavis to Present at Barclays Global Healthcare Conference 8:00 a.m. March 4, 2014 - PR Newswire - PRF
Actavis Confirms Generic Colcrys® Patent Challenge 4:05 p.m. Feb. 28, 2014 - PR Newswire - PRF
Actavis Confirms Generic Multaq® Patent Challenge 8:00 a.m. Feb. 28, 2014 - PR Newswire - PRF
Actavis Net Revenue Increases 59% to $2.779 Billion in Fourth Quarter 2013; Non-GAAP EPS Increases 99% to $3.17 7:00 a.m. Feb. 20, 2014 - PR Newswire - PRF
Actavis to Present at Citi's 2014 Global Healthcare Conference 4:25 p.m. Feb. 19, 2014 - PR Newswire - PRF
Critical Alerts For Actavis, athenahealth, Seattle Genetics, JP Morgan Chase, and SodaStream Released By InvestorsObserver 9:31 a.m. Feb. 19, 2014 - PR Newswire - PRF
Actavis to buy Forest Labs for $25B and GT Advanced Tech acquires exclusive rights from Kyma Tech 12:31 a.m. Feb. 19, 2014 - ACCESSWIRE
Acquisition of Forest Laboratories, Inc. by Actavis plc May Not Be in Shareholders' Best Interests 9:02 p.m. Feb. 18, 2014 - PR Newswire - PRF
Actavis to Cancel Q4 and FY 2013 Earnings Call Previously Scheduled for Thursday, February 20, 2014 5:13 p.m. Feb. 18, 2014 - PR Newswire - PRF
Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Forest Laboratories, Inc. Stockholders 5:01 p.m. Feb. 18, 2014 - BusinessWire - BZX
Fitch Affirms Actavis at 'BBB-' on Forest Labs Acquisition; Outlook Stable 2:52 p.m. Feb. 18, 2014 - BusinessWire - BZX
FOREST SHAREHOLDERS NOTICE:Johnson & Weaver, LLP Announces Investigation of the Forest Laboratories, Inc. Proposed Acquisition by Actavis plc 9:43 a.m. Feb. 18, 2014 - BusinessWire - BZX
INVESTOR BUYOUT ALERT - Offer to Acquire Forest Laboratories - Shareholder Rights Law Firm Tripp Levy PLLC Seeks Higher Price And More Information For Shareholders 8:00 a.m. Feb. 18, 2014 - PR Newswire - PRF
Actavis to Acquire Forest Laboratories, Inc. for ~$25 Billion in an Equity and Cash Transaction 7:00 a.m. Feb. 18, 2014 - BusinessWire - BZX
Actavis to Acquire Forest Laboratories, Inc. for ~$25 Billion in an Equity and Cash Transaction 7:00 a.m. Feb. 18, 2014 - PR Newswire - PRF
Actavis to Host Fourth Quarter 2013 Earnings Conference Call and Webcast 8:00 a.m. Feb. 11, 2014 - PR Newswire - PRF
Actavis Confirms Generic Treanda® Patent Challenge 8:00 a.m. Feb. 4, 2014 - PR Newswire - PRF
UK drug rejection, patent concerns take a bite out of Celgene shares 1:33 p.m. March 14, 2014 - blogs.marketwatch.com
Mylan to start selling generic Celebrex in May 7:22 a.m. March 13, 2014 - MarketWatch.com
Pfizer loses Celebrex patent ruling; shares halted but effect muted 3:21 p.m. March 12, 2014 - blogs.marketwatch.com
Staples awash in red; eBay up as Icahn posts new letter 4:09 p.m. March 6, 2014 - Victor Reklaitis
Icahn Enterprises reports profit up 144% in 2013 10:22 a.m. March 3, 2014 - MarketWatch
Citadel hedge fund’s recent moves 11:12 a.m. Feb. 25, 2014 - Insider Monkey
Stocks rally; S&P 500 ends right below record 4:45 p.m. Feb. 24, 2014 - Victor Reklaitis
U.S. stock market is starting to ride a tech M&A wave 5:31 a.m. Feb. 24, 2014 - Wallace Witkowski
Actavis continues hot streak with better-than-expected earnings 11:21 a.m. Feb. 20, 2014 - blogs.marketwatch.com
Actavis swings to loss on charges, write-downs 8:03 a.m. Feb. 20, 2014 - MarketWatch.com
Pharma megamergers bring higher profits, better returns, study says 1:59 p.m. Feb. 19, 2014 - blogs.marketwatch.com
Actavis, Forest shares continue their climb in aftermath of $25 billion deal 11:03 a.m. Feb. 19, 2014 - blogs.marketwatch.com
U.S. stocks edge up; Nasdaq gains for 8th day in a row 4:38 p.m. Feb. 18, 2014 - Anora Mahmudova
Forest Laboratories, Actavis surge on buyout deal 4:10 p.m. Feb. 18, 2014 - Ben Eisen
S&P 500, Nasdaq extend win streaks but Dow dips: stock market live blog recap 4:06 p.m. Feb. 18, 2014 - blogs.marketwatch.com
Forest buyout may not spell the end of dealmaking for Actavis 3:00 p.m. Feb. 18, 2014 - blogs.marketwatch.com
Pharma ETFs pop on the Actavis-Forest deal 2:07 p.m. Feb. 18, 2014 - blogs.marketwatch.com
Investors drive up price of Actavis-Forest deal 11:14 a.m. Feb. 18, 2014 - blogs.marketwatch.com
Actavis shares jump 7.8% on Forest Lab deal 9:35 a.m. Feb. 18, 2014 - Sue Chang
U.S. stock futures trim rise; Forest Labs soars 9:14 a.m. Feb. 18, 2014 - Sara Sjolin
Veteran Investor's Top Biotech and Drug Stocks 7:07 a.m. Today - Barrons.com
Actavis Prescribes Profits via M&A and Generic Drugs 8:27 p.m. March 16, 2014 - InvestorPlace.com
Actavis, Mylan to Benefit from Celebrex Ruling - Analyst Blog 5:20 p.m. March 14, 2014 - Zacks.com
Horizon Pharma Banks On Two-For-One Arthritis Drugs 1:05 p.m. March 14, 2014 - Investors Business Daily
Why Teva May Be Back From the Dead 10:07 a.m. March 14, 2014 - 247WallSt.com
Teva Pharmaceuticals Stock Could Rise 30% 12:54 a.m. March 14, 2014 - Barrons.com
FDA Approves Mallinckrodt's Xartemis XR - Analyst Blog 6:00 p.m. March 13, 2014 - Zacks.com
Narrower-than-Expected Loss at Supernus - Analyst Blog 9:40 a.m. March 13, 2014 - Zacks.com
Pfizer Says Court Invalidates Celebrex Patent 7:51 a.m. March 13, 2014 - The Wall Street Journal Interactive Edition
Pfizer Loses Patent On Celebrex, Plans To Appeal 2:59 p.m. March 12, 2014 - Investors Business Daily
Icahn Makes Case to eBay Investors 2:32 p.m. March 12, 2014 - The Wall Street Journal Interactive Edition
Greenberg: What You May Have Missed 9:33 a.m. March 12, 2014 - TheStreet.com
Will Horizon Pharma Spike Again On Quarterly Report? 7:02 a.m. March 12, 2014 - Investors Business Daily
How To Invest: Seek Stock Ideas In Sector Leaders 4:23 p.m. March 11, 2014 - Investors Business Daily
Actavis PLC (ACT): Today's Featured Drugs Laggard 5:01 p.m. March 10, 2014 - TheStreet.com
3 Stocks Underperforming Today In The Drugs Industry 1:04 p.m. March 10, 2014 - TheStreet.com
Forest Labs/Adamas Seek FDA Approval - Analyst Blog 5:00 p.m. March 7, 2014 - Zacks.com
Highflying Drug, Biotech Stocks Take Rare Drubbing 4:49 p.m. March 7, 2014 - Investors Business Daily
Merck KGaA Misses 2013 Earnings & Rev Ests - Analyst Blog 10:30 a.m. March 7, 2014 - Zacks.com
Columbia Labs buys back shares 9:30 a.m. March 7, 2014 - Seeking Alpha
New Drug Applications, Earnings Release Schedules, Drug Designations, New Services, and Clinical Trials - Analyst Notes on Actavis, Intercept, GW Pharmaceuticals, Galena, and Conatus 8:00 a.m. March 13, 2014 - PR Newswire - PRF
Actavis Confirms Favorable Ruling in Generic Celebrex® Patent Suit 5:35 p.m. March 12, 2014 - PR Newswire - PRF
Columbia Laboratories Repurchases 1.4 Million Shares of Common Stock from Actavis 6:50 a.m. March 7, 2014 - PR Newswire - PRF
Actavis to Present at Barclays Global Healthcare Conference 8:00 a.m. March 4, 2014 - PR Newswire - PRF
Actavis Confirms Generic Colcrys® Patent Challenge 4:05 p.m. Feb. 28, 2014 - PR Newswire - PRF
Actavis Confirms Generic Multaq® Patent Challenge 8:00 a.m. Feb. 28, 2014 - PR Newswire - PRF
Actavis Net Revenue Increases 59% to $2.779 Billion in Fourth Quarter 2013; Non-GAAP EPS Increases 99% to $3.17 7:00 a.m. Feb. 20, 2014 - PR Newswire - PRF
Actavis to Present at Citi's 2014 Global Healthcare Conference 4:25 p.m. Feb. 19, 2014 - PR Newswire - PRF
Critical Alerts For Actavis, athenahealth, Seattle Genetics, JP Morgan Chase, and SodaStream Released By InvestorsObserver 9:31 a.m. Feb. 19, 2014 - PR Newswire - PRF
Actavis to buy Forest Labs for $25B and GT Advanced Tech acquires exclusive rights from Kyma Tech 12:31 a.m. Feb. 19, 2014 - ACCESSWIRE
Acquisition of Forest Laboratories, Inc. by Actavis plc May Not Be in Shareholders' Best Interests 9:02 p.m. Feb. 18, 2014 - PR Newswire - PRF
Actavis to Cancel Q4 and FY 2013 Earnings Call Previously Scheduled for Thursday, February 20, 2014 5:13 p.m. Feb. 18, 2014 - PR Newswire - PRF
Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Forest Laboratories, Inc. Stockholders 5:01 p.m. Feb. 18, 2014 - BusinessWire - BZX
Fitch Affirms Actavis at 'BBB-' on Forest Labs Acquisition; Outlook Stable 2:52 p.m. Feb. 18, 2014 - BusinessWire - BZX
FOREST SHAREHOLDERS NOTICE:Johnson & Weaver, LLP Announces Investigation of the Forest Laboratories, Inc. Proposed Acquisition by Actavis plc 9:43 a.m. Feb. 18, 2014 - BusinessWire - BZX
INVESTOR BUYOUT ALERT - Offer to Acquire Forest Laboratories - Shareholder Rights Law Firm Tripp Levy PLLC Seeks Higher Price And More Information For Shareholders 8:00 a.m. Feb. 18, 2014 - PR Newswire - PRF
Actavis to Acquire Forest Laboratories, Inc. for ~$25 Billion in an Equity and Cash Transaction 7:00 a.m. Feb. 18, 2014 - BusinessWire - BZX
Actavis to Acquire Forest Laboratories, Inc. for ~$25 Billion in an Equity and Cash Transaction 7:00 a.m. Feb. 18, 2014 - PR Newswire - PRF
Actavis to Host Fourth Quarter 2013 Earnings Conference Call and Webcast 8:00 a.m. Feb. 11, 2014 - PR Newswire - PRF
Actavis Confirms Generic Treanda® Patent Challenge 8:00 a.m. Feb. 4, 2014 - PR Newswire - PRF
